KPTI insider filing shows 12,799 RSUs to Chief Accounting Officer

Rhea-AI Filing Summary

Karyopharm Therapeutics (KPTI) reported a Form 4 showing Chief Accounting Officer Kristin Abate received 12,799 restricted stock units (RSUs) on October 15, 2025 at a stated price of $0. The RSUs convert into common stock on a one-for-one basis.

According to the award terms, 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026. Following this award, Abate beneficially owned 22,845 shares, reported as Direct (D) ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Abate Kristin

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	12,799	$0.00	--

Holdings After Transaction: Common Stock — 22,845 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abate Kristin

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		A		12,799(1)	A	$0	22,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as follows: 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026.

	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	10/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Karyopharm Therapeutics (KPTI) disclose in this Form 4?

A grant of 12,799 RSUs to Chief Accounting Officer Kristin Abate on October 15, 2025, at a stated price of $0.

How do the RSUs awarded to KPTI’s CAO vest?

2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026.

What is the conversion ratio for the RSUs disclosed by KPTI?

The RSUs convert into Karyopharm common stock on a one-for-one basis.

How many KPTI shares were beneficially owned after the transaction?

Beneficial ownership was reported as 22,845 shares, held as Direct (D) ownership.

Who is the reporting person in KPTI’s Form 4 filing?

The reporting person is Kristin Abate, Karyopharm’s Chief Accounting Officer.

Was this Form 4 filed for non-derivative or derivative securities?

It reports a non-derivative acquisition of common stock underlying RSUs.